GlassScriptPhysician profile
Mayank N Dave
NPI 1275738148
$2,391.16
in general payments reported to CMS, 2019-2025
16 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $27.59 · 2021: $780 · 2022: $560 · 2023: $248 · 2024: $379 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,324.21 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $161.00 | 2019-2025 | Lifevest |
| Ucb, INC. | $151.51 | 2022-2024 | Briviact |
| Asahi Intecc USA, INC. | $127.06 | 2023-2024 | Peripheral Vascular, Asahi Ptca Guide Wire |
| La Jolla Pharmaceutical Company | $107.40 | 2019-2024 | Giapreza |
| Sunovion Pharmaceuticals INC. | $80.38 | 2019 | |
| Chiesi USA, INC. | $77.83 | 2023-2025 | Cleviprex |
| Pfizer INC. | $70.13 | 2020-2025 | |
| Revance Therapeutics, INC. | $65.91 | 2024 | Daxxify |
| Abbvie INC. | $63.58 | 2023-2025 | Botox |
| Novartis Pharmaceuticals Corporation | $55.16 | 2019-2023 | |
| Biomerieux INC | $31.12 | 2019 | |
| Merck Sharp & Dohme LLC | $29.95 | 2023 | Recarbrio, Zerbaxa, Dificid |
| Mylan Specialty L.P. | $15.72 | 2023 | Yupelri |
| Ultragenyx Pharmaceutical INC. | $15.26 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.94 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayank Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.